China National Pharmaceutical Group Corporation: Holding subsidiary signs 10.5 million yuan drug market authorization transfer contract.

China National Pharmaceutical Group announced that its holding subsidiary, China National Pharmaceutical Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd., has signed a "Drug Marketing License Transfer Agreement" with Shanghai Boyue Biotechnology Co., Ltd. The agreement involves the transfer of the marketing license and related rights of the registered ethopropazine hydrochloride tablets that Shanghai Boyue is applying for. The total transfer fee is 10.5 million RMB. This drug is a central muscle relaxant, clinically indicated for improving conditions such as cervical shoulder arm syndrome, adhesive capsulitis, and muscle tension in low back pain, as well as treating spastic paralysis caused by diseases. According to the MiiNii internet database, the sales revenue of ethopropazine hydrochloride tablets in 2024 in public medical institutions and retail markets nationwide is 499 million RMB.